Rebio Pharma

ReBio Pharma is a European biotechnology company developing novel, targeted, vision-preserving therapies for ocular oncology that achieve precise exposure at the site of disease. The lead program, RBP-01, applies a proprietary therapeutic amplifier technology to deliver potent, localized tumor control in uveal melanoma. ReBio is advancing RBP-01 toward the clinic (Q1 2026), while pursuing the development of additional assets targeting uveal melanoma and retinoblastoma, expanding therapeutic possibilities of existing treatments with targeted drug exposure. For more information, please visit